US EditionTrump, AstraZeneca announce US drug pricing deal at White House
AstraZeneca will offer Medicaid drugs at the lowest prices in developed countries and invest $50 billion in U.S. manufacturing, creating 3,600 jobs, officials said.
- President Donald Trump announced a deal with AstraZeneca to provide Medicaid patients with discounted prescription drugs under a 'most-favored nation' policy.
- AstraZeneca will invest $50 billion in U.S. manufacturing and research, creating approximately 3,600 jobs in Virginia.
- The agreement aims to align U.S. drug prices with the lowest prices in other developed countries, significantly benefiting low-income patients.
- The deal intends to reduce drug costs for Americans, countering high pharmaceutical prices.
200 Articles
200 Articles
Trump, AstraZeneca announce US drug pricing deal at White House - West Hawaii Today
President Donald Trump unveiled a deal with UK-based drugmaker AstraZeneca on Friday under which the company will sell some medicines at a discount to the government’s Medicaid health plan in exchange for tariff relief, similar to a drug pricing pact reached last week with Pfizer.
Trump Strikes Landmark Deal with AstraZeneca to Lower Drug Prices for Americans
In a dramatic escalation of his “America First” agenda, President Donald Trump announced a sweeping new agreement with pharmaceutical giant AstraZeneca aimed at slashing prescription drug costs for American patients. The deal, revealed Friday, makes AstraZeneca the second major company—after Pfizer—to commit to “most-favored-nation” pricing, meaning the United States will pay no more for drugs than any other developed nation. Speaking from the W…
Donald Trump urges pharmaceutical companies to reduce their prices. Now, a second company has entered into an agreement with AstraZeneca. In return, there should be tariff reductions.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
